MTM(688029)2025-02-24 11:20Financial Performance - The total operating revenue for 2024 reached RMB 2,760.51 million, an increase of 14.47% compared to the previous year[3] - The net profit attributable to the parent company was RMB 551.67 million, reflecting a growth of 13.53% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 542.87 million, up 17.21% from the previous year[3] - The basic earnings per share increased to RMB 2.94, a rise of 13.51% compared to the same period last year[3] - The total assets at the end of the reporting period were RMB 4,759.37 million, an increase of 8.35% from the beginning of the period[3] - The equity attributable to the parent company was RMB 3,831.03 million, which is a 6.07% increase from the beginning of the period[3] - The weighted average return on net assets improved to 14.94%, an increase of 0.69 percentage points year-on-year[3] Strategic Focus - The company continues to focus on independent research and development, medical engineering innovation, and industry-academia collaboration to enhance market presence[6] - The overseas channel coverage has further expanded, indicating a strategic move towards international market growth[6] Risk Awareness - The company emphasizes the importance of risk awareness as the financial data is preliminary and unaudited, urging investors to consider investment risks[7]